Abstracts tagged "DMARDs"

Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Burkhard Moeller¹, Axel Finckh², Jose Maria Alvaro-Gracia³, Godehard Scholz¹, Daniel Aletaha⁴, Francesca Biondo⁵, Sander Strengholt⁶, Jose L Rivas⁷, Carol A Connell⁸ and Harry Shi⁹, ¹Inselspital-University Hospital, Bern, Switzerland, ²University Hospital of Geneva, Geneva, Switzerland, ³Hospital Universitario de La Princesa, Madrid, Spain, ⁴Medical University of Vienna, Vienna, Austria, ⁵Pfizer Inc, Rome, Italy, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer SLU, Madrid, Spain, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…
Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Pia Mercedes Lois¹, Cristina Vadillo Font¹, Dalifer Freites Núñez², Isabel Hernández-Rodríguez¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…
Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Andreas Kerschbaumer¹, Harald Herkner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department for Emergency Medicine, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…
Abstract Number: 681 • 2018 ACR/ARHP Annual Meeting
Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor
Dan Gromer¹, Laura C. Coates², Oliver FitzGerald³, Blanca Himes⁴, Philip Helliwell⁵ and Alexis Ogdie⁶, ¹University of Pennsylvania, Medical Student, Philadelphia, PA, ²University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁴Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁵LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an…
Abstract Number: 1538 • 2018 ACR/ARHP Annual Meeting
Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Lydia A Alcazar¹, Dalifer Freites Núñez¹, Isabel Hernández-Rodríguez², Judit Font Urgelles², Pia Mercedes Lois², Benjamín Fernández-Gutiérrez², Juan A Jover Jover¹ and Zulema Rosales Rosado^1,2, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In rheumatology, we are aware of the possibility to develop adverse drug reactions (ADR) to the widely used Disease Modifying Drugs (DMARD). We are…
Abstract Number: 2464 • 2018 ACR/ARHP Annual Meeting
Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis
Jorge Florez-Suarez¹, Paul Mendez², Edna Bermudez¹, Paola Coral² and Gerardo Quintana-Lopez^1,3, ¹Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogotá, Colombia, ²Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogota, Colombia, ³School of medicine, Universidad Nacional de Colombia, Bogotá, Colombia
Background/Purpose: Current guidelines for RA treatment are focused on the importance of defining the duration of symptoms before diagnosis to achieve better outcomes. This concept…
Abstract Number: 2888 • 2018 ACR/ARHP Annual Meeting
Concomitant Csdmards Influence Clinical Response to TNF Inhibitors Only in Overweight Patients with Axial Spondyloarthritis
Borja Hernández-Breijo¹, Victoria Navarro-Compán¹, Ana Martínez¹, Andrea Jochems¹, Alejandro Villalba², Diana Peiteado³, Eva L. Kneepkens⁴, Gerrit Wolbink⁴, Theo Rispens⁵, Dora Pascual-Salcedo¹, Alejandro Balsa¹ and Chamaida Plasencia¹, ¹Immuno-Rheumatology research group, IdiPaz. La Paz University Hospital, Madrid, Spain, ²Rheumatology, La Paz University Hospital, Madrid, Spain, ³Hospital Universitario La Paz, Madrid, Spain, ⁴Rheumatology, Reade, Amsterdam, Netherlands, ⁵Immunopathology, Sanquin Research, Amsterdam, Netherlands
Background/Purpose: In patients with axial spondyloarthritis (axSpA), the use of conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), such as methotrexate (MTX) and sulfasalazine (SSZ), as well…
Abstract Number: 270 • 2018 ACR/ARHP Annual Meeting
Gaps in Knowledge about the Ontario Trillium Drug Program
Ambika Gupta¹, Heather Khey Beldman², Caroline Averns³ and Henry Averns³, ¹Internal Medicine, Queen's University, Kingston, ON, Canada, ²Department of Family Medicine, Queen's University, Kingston, ON, Canada, ³Private Practice, Kingston, ON, Canada
Background/Purpose: Medication costs for patients with a rheumatic disease can add up as they may be on numerous and/or costly medications including anti-inflammatory medications, disease-modifying…
Abstract Number: 688 • 2018 ACR/ARHP Annual Meeting
Real Life Analysis of a Latin America Tertiary Spondyloarthritis Single-Center: High Frequency of Peripheral Involvement and Use of Synthetic Dmard
Andrea Shimabuco¹, Julio CB Moraes¹, Percival Sampaio-Barros², Cláudia Goldenstein-Schainberg¹, Celio R. Gonçalves¹, Ana CM Ribeiro¹ and Carla GS Saad¹, ¹Rheumatology Division, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Rheumatology, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, BR., São Paulo, Brazil
Background/Purpose: The use of synthetic DMARDS (sDMARDs) in spondyloarthritis (SpA) has been increasingly questioned and restricted to peripheral disease, on the other hand, the use…
Abstract Number: 1541 • 2018 ACR/ARHP Annual Meeting
The Safety Profile of Iguratimod in Real Clinical Practice: Analysis of 491 Patients with Rheumatoid Arthritis
Yukihiko Ikeda¹, Ryo Rokutanda¹, Sho Fukui¹, Haruki Sawada², Mitsuru Watanabe³, Ayako Koido³, Yuko Kataoka¹, Rui Kawato⁴, Haruyuki Yanaoka⁵, Masei Suda⁶, Yuri Ohara⁷, Hiromichi Tamaki¹, Hisanori Shimizu⁶, Tokutaro Tsuda¹, Ken-ichi Yamaguchi⁸, Mitsumasa Kishimoto¹ and Masato Okada¹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ³Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, ⁵St. Luke's International Hospital, Tokyo, Japan, ⁶Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, ⁷Allergy & Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁸Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan
The retention rate and safty profile of iguratimod in real clinical practice: Analysis of 456 patients with Rheumatoid arthritis. Abstract Background/Purpose: Iguratimod is one of…
Abstract Number: 2466 • 2018 ACR/ARHP Annual Meeting
Prolonged Delay in Presentation to Rheumatologists for Hispanic Patients with Rheumatoid Arthritis Contributes to Later Diagnosis and Treatment
Mariam Riad¹, Daniel Dunham², Jacquelin R. Chua¹, Theodore Pincus¹, Najia Shakoor¹, Sobia Hassan¹, Joel A. Block¹ and Isabel Castrejón¹, ¹Division of Rheumatology, Rush University Medical Center, Chicago, IL, ²Division of Internal Medicine, Rush University Medical Center, Chicago, IL
Background/Purpose: Disparities in the initiation of disease modifying anti-rheumatic drugs (DMARDs) in ethnic minorities have been described in rheumatoid arthritis (RA) patients in the US…
Abstract Number: 305 • 2018 ACR/ARHP Annual Meeting
Introduction and Value of a Shortened Psamris-7 in Psa-Patients before and after Treatment Escalation to Bdmard Using High Resolution MRI
Philipp Sewerin¹, Daniel Benjamin Abrar², Christine Goertz³, Marco Jung⁴, Matthias Schneider⁵, Benedikt Ostendorf¹ and Christoph Schleich⁶, ¹Department and Hiller-Research-Unit for Rheumatology, Heinrich-Heine University, Düsseldorf, Germany, ²Department for diagnostic and interventional Radiology, Heinrich-Heine-Universitiy, Duesseldorf, Germany, ³Department and Hiller-Research-Unit for Rheumatology, Heinrich-Heine-Universitiy, Duesseldorf, Germany, ⁴Department and Hiller-Research-Unit for Rheumatologie, Heinrich-Heine Universitiy, Duesseldorf, Germany, ⁵Department and Hiller-Research-Unit for Rheumatology, Heinrich-Heine University, Duesseldorf, Germany, ⁶Department for diagnostic and interventional Radiology, Heinrich-Heine University, Duesseldorf, Germany
Background/Purpose: The aim of the study was to evaluate a simplified version of the OMERACT Psoriasis Arthritis Magnetic Resonance Imaging Score (PsAMRIS) to seven regions…
Abstract Number: 697 • 2018 ACR/ARHP Annual Meeting
Clinical Results of Patients with Peripheral Psoriatic Arthritis Not Receiving Biological Therapy in a Multidisciplinary Unit
Clara Pérez-Velásquez¹, Maria Luz Garcia Vivar², Silvia Perez Barrio³, Eva Galindez-Agirregoikoa¹, Esther Ruíz Lucea¹, Ignacio Torre-Salaberri⁴, Olaia Fernández-Berrizbeitia¹, Ana Rosa Inchaurbe Pellejero², Juan Blanco Madrigal¹, Edurne Guerrero Basterretxea², Itziar Calvo Zorrilla², Oihane Ibarguengoitia², David Montero², Natalia Rivera-García¹, Maria Jesus Allande Lopez Linares¹ and Iñigo Gorostiza-Hormaetxe⁵, ¹Rheumatology, University Hospital of Basurto, Bilbao, Spain, ²Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Dermatology, University Hospital of Basurto, Bilbao, Spain, ⁴Rheumatology, Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, ⁵Unit of Research, University Hospital of Basurto, Bilbao, Spain
Background/Purpose: We consider multidisciplinary management necessary, especially in a subgroup of patients with Psoriatic Arthritis (PsA) for complexity, cutaneous and / or joint involvement. Despite…
Abstract Number: 1542 • 2018 ACR/ARHP Annual Meeting
Real-World Data from a Post-Approval Safety Surveillance Study of Tofacitinib Vs Biologic Dmards and Conventional Synthetic Dmards: Five-Year Results from a US-Based Rheumatoid Arthritis Registry
Joel Kremer¹, Laura C. Cappelli², Carol J. Etzel³, Jeffrey Greenberg³, Jamie Geier⁴, Ann Madsen⁴, Connie Chen⁴, Alina Onofrei³, Christine J Barr³, Dimitrios A. Pappas³, Kimberly J Dandreo³, Andrea Shapiro⁵, Carol A Connell⁶ and Arthur Kavanaugh⁷, ¹Albany Medical College and the Center for Rheumatology, Albany, NY, ²Johns Hopkins University, Baltimore, MD, ³Corrona LLC, Waltham, MA, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Peapack, NJ, ⁶Pfizer Inc, Groton, CT, ⁷University of California, San Diego School of Medicine, La Jolla, San Diego, CA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. A prospective observational 5-year study, embedded within the US Corrona RA registry,…
Abstract Number: 2468 • 2018 ACR/ARHP Annual Meeting
Window or No Window? Earlier Is Better When Treating Rheumatoid Arthritis
Sytske Anne Bergstra¹, Joy A. van der Pol², Nagmeh Riyazi³, Yvonne P. Goekoop-Ruiterman³, Arvind Chopra⁴, José António P. da Silva⁵, Pit J.S.M. Kerstens⁶, Willem F. Lems⁷, S. Tsonaka⁸, Tom W.J. Huizinga¹ and Cornelia F. Allaart¹, ¹Department of Rheumatology, LUMC, Leiden, Netherlands, ²Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ³HAGA Hospital, The Hague, Netherlands, ⁴Center for Rheumatic Diseases, Pune, India, ⁵Department of rheumatology, Centro Hospitalar e Universitário de Coimbra (SRHUC), Coimbra, Portugal, ⁶Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ⁷Department of Rheumatology, VU Medical Center, Amsterdam, Netherlands, ⁸Department of Medical Statistics and Bioinformatics, LUMC, Leiden, Netherlands
Background/Purpose: Previous reports on a window of opportunity (WOO) in rheumatoid arthritis (RA) may be related to the use of slow acting csDMARDs. We investigated…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].